Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: The primary care setting

Journal of the National Medical Association

Volumn 98, Issue 1, 2006, Pages 58-62

  Hoskins, Michael H ^a,b   Jacobson, Terry A ^a,b,c  

^a Emory University ^*

^b EMORY UNIVERSITY   (United States)

^c Department of Medicine   (United States)

Author keywords

Cholesterol; Coronary heart disease; Lipids; Prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; COLESTYRAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT FAILURE; URBAN POPULATION;

CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 30444444206     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ryan T, Antman E, Brooks N, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890-911.
2. The Scandinavian Simvastatin Survival Study. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;334:1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events (CARE) trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-anatysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
6. Downs JR, Clearfield M, Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the Nationol Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA. 2001;285:2486-2497.
8. Fonarow GC. Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. Vasc Med. 2002; 7:187-194.
9. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. Data from the national registry of myocardial infarction 3. Circulation. 2001;103:38-44.
10. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257-261.
11. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary heart disease. Am J Cardiol. 1999;83:1303-1307.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA. 1993;269:3015-3023.
13. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
14. Dressler DD, Jacobson TA. Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease. Am J Cardiol. 2004;93:1167-1170.
15. Headrick LA, Speroff T, Pelecanos HI, et al. Efforts to improve compliance with the National Cholesterol Education Program guidelines. Results of a randomized controlled trial. Arch Intern Med. 1992;152:2490-2496.
16. Labresh KA, Owen P, Alteri C, et al. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. Am J Cardiol. 2000;85:23A-29A.
17. Foley KA, Simpson RJ, Crouse JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
18. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
19. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.